(1) This therapy produces gradual, natural changes that align with the bodys rhythm
Im only 51 so for me thats an accomplishment
PubMed laboratory research record [PMID: 18209454] PubMed record related to this compound for laboratory literature review
Tschop recounted his research with DiMarchi and that of others while he accepted the 2023 Banting Medal for Scientific Achievement at the 2023 American Diabetes Association Scientific Sessions.5 The FDA approved the first GLP-1 agonist, twice-a-day Byetta (exenatide), in 2005.1 Since then, several newer and more powerful medications in the GLP-1 agonist class, such as liraglutide and semaglutide, have received FDA approval for type 2 diabetes, with a higher dose of semaglutide FDA approved for weight loss.2 In mid-2022, the first dual agonist, tirzepetide (a combination of a GLP-1 agonist and a GIP), was FDA approved for type 2 diabetes
Journal of the American College of Nutrition, 36 (8), 631639